Literature DB >> 27503405

Ten-year hemoglobin A1c trajectories and outcomes in type 2 diabetes mellitus: The Diabetes & Aging Study.

Neda Laiteerapong1, Andrew J Karter2, Howard H Moffet2, Jennifer M Cooper3, Robert D Gibbons4, Jennifer Y Liu2, Yue Gao3, Elbert S Huang3.   

Abstract

AIMS: To classify trajectories of long term HbA1c values in patients after diagnosis of type 2 diabetes and examine each trajectory's associations with subsequent microvascular and macrovascular events and mortality.
METHODS: A longitudinal follow-up of 28,016 patients newly diagnosed with type 2 diabetes was conducted. Latent growth mixture modeling was used to identify ten-year HbA1c trajectories. Cox proportional hazards models were used to assess how HbA1c trajectories were associated with events (microvascular and macrovascular) and mortality.
RESULTS: We identified 5 HbA1c trajectories: "low stable" (82.5%), "moderate increasing late" (5.1%), "high decreasing early" (4.9%), "moderate peaking late" (4.1%) and "moderate peaking early" (3.3%). After adjusting for average HbA1c, compared to the low stable trajectory, all non-stable trajectories were associated with higher incidences of microvascular events (hazard ratio (HR) range, 1.28 (95% CI, 1.08-1.53) (high decreasing early) to 1.45 (95% CI, 1.20-1.75) (moderate peaking early)). The high decreasing early trajectory was associated with an increased mortality risk (HR, 1.27 (95% CI, 1.03-1.58)). Trajectories were not associated with macrovascular events.
CONCLUSIONS: Non-stable HbA1c trajectories were associated with greater risk of microvascular events and mortality. These findings suggest a potential benefit of early diabetes detection, prioritizing good glycemic control, and maintaining control over time.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Epidemiology; Glycemic control; Legacy effect; Microvascular disease; Mortality

Mesh:

Substances:

Year:  2016        PMID: 27503405      PMCID: PMC5209280          DOI: 10.1016/j.jdiacomp.2016.07.023

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  32 in total

1.  Fasting plasma glucose variability as a risk factor of retinopathy in Type 2 diabetic patients.

Authors:  José A Gimeno-Orna; Francisco J Castro-Alonso; Beatriz Boned-Juliani; Luis M Lou-Arnal
Journal:  J Diabetes Complications       Date:  2003 Mar-Apr       Impact factor: 2.852

2.  Cohort Profile: The Diabetes Study of Northern California (DISTANCE)--objectives and design of a survey follow-up study of social health disparities in a managed care population.

Authors:  Howard H Moffet; Nancy Adler; Dean Schillinger; Ameena T Ahmed; Barbara Laraia; Joe V Selby; Romain Neugebauer; Jennifer Y Liu; Melissa M Parker; Margaret Warton; Andrew J Karter
Journal:  Int J Epidemiol       Date:  2008-03-07       Impact factor: 7.196

3.  Standards of medical care in diabetes--2014.

Authors: 
Journal:  Diabetes Care       Date:  2014-01       Impact factor: 19.112

4.  Use and characteristics of electronic health record systems among office-based physician practices: United States, 2001-2013.

Authors:  Chun-Ju Hsiao; Esther Hing
Journal:  NCHS Data Brief       Date:  2014-01

5.  Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study.

Authors:  M Muggeo; G Zoppini; E Bonora; E Brun; R C Bonadonna; P Moghetti; G Verlato
Journal:  Diabetes Care       Date:  2000-01       Impact factor: 19.112

6.  Missed appointments and poor glycemic control: an opportunity to identify high-risk diabetic patients.

Authors:  Andrew J Karter; Melissa M Parker; Howard H Moffet; Ameena T Ahmed; Assiamira Ferrara; Jennifer Y Liu; Joe V Selby
Journal:  Med Care       Date:  2004-02       Impact factor: 2.983

7.  Intrapersonal HbA(1c) variability and the risk of progression of nephropathy in patients with Type 2 diabetes.

Authors:  S Rodríguez-Segade; J Rodríguez; J M García López; F F Casanueva; F Camiña
Journal:  Diabet Med       Date:  2012-12       Impact factor: 4.359

8.  Validation of a combined comorbidity index.

Authors:  M Charlson; T P Szatrowski; J Peterson; J Gold
Journal:  J Clin Epidemiol       Date:  1994-11       Impact factor: 6.437

9.  HbA1c variability is associated with microalbuminuria development in type 2 diabetes: a 7-year prospective cohort study.

Authors:  C C Hsu; H Y Chang; M C Huang; S J Hwang; Y C Yang; Y S Lee; S J Shin; T Y Tai
Journal:  Diabetologia       Date:  2012-08-26       Impact factor: 10.122

10.  HbA(1c) variability and the development of microalbuminuria in type 2 diabetes: Tsukuba Kawai Diabetes Registry 2.

Authors:  A Sugawara; K Kawai; S Motohashi; K Saito; S Kodama; Y Yachi; R Hirasawa; H Shimano; K Yamazaki; H Sone
Journal:  Diabetologia       Date:  2012-05-12       Impact factor: 10.122

View more
  30 in total

1.  Implementation of A1C Point-of-Care Testing: Serving Under-Resourced Adults With Type 2 Diabetes in a Public Health Department.

Authors:  Mary Nicole John; Kathryn E Kreider; Julie A Thompson; Katherine Pereira
Journal:  Clin Diabetes       Date:  2019-07

2.  Diabetes and Humor: A Preliminary Investigation.

Authors:  David S Greene; Nancy Dunavant King; Jean Bryan Coe
Journal:  Diabetes Spectr       Date:  2020-05

3.  Capsule Commentary for Raghavan et al., Association of Glycemic Control Trajectory with Short-term Mortality in Diabetes Patients with High Cardiovascular Risk: a Joint Latent Class Modeling Study.

Authors:  Scott Christopher Blaszak; Dexter Gingery Nye; Hannah Hyland Walton
Journal:  J Gen Intern Med       Date:  2020-08       Impact factor: 5.128

Review 4.  The legacy effect in diabetes: are there long-term benefits?

Authors:  Rachel Folz; Neda Laiteerapong
Journal:  Diabetologia       Date:  2021-08-14       Impact factor: 10.460

5.  Stacked classifiers for individualized prediction of glycemic control following initiation of metformin therapy in type 2 diabetes.

Authors:  Dennis H Murphree; Elaheh Arabmakki; Che Ngufor; Curtis B Storlie; Rozalina G McCoy
Journal:  Comput Biol Med       Date:  2018-10-16       Impact factor: 4.589

6.  A risk score including body mass index, glycated haemoglobin and triglycerides predicts future glycaemic control in people with type 2 diabetes.

Authors:  Dorijn F L Hertroijs; Arianne M J Elissen; Martijn C G J Brouwers; Nicolaas C Schaper; Sebastian Köhler; Mirela C Popa; Stylianos Asteriadis; Steven H Hendriks; Henk J Bilo; Dirk Ruwaard
Journal:  Diabetes Obes Metab       Date:  2017-11-24       Impact factor: 6.577

7.  Identification of Unique Antigenic Determinants in the Amino Terminus of IA-2 (ICA512) in Childhood and Adult Autoimmune Diabetes: New Biomarker Development.

Authors:  Maria Acevedo-Calado; Eddie A James; Michael P Morran; Susan L Pietropaolo; Qin Ouyang; David Arribas-Layton; Marco Songini; Marco Liguori; Anna Casu; Richard J Auchus; Shuai Huang; Liping Yu; Aaron Michels; Roberto Gianani; Massimo Pietropaolo
Journal:  Diabetes Care       Date:  2017-02-07       Impact factor: 19.112

8.  Health Insurance Is Associated with Decreased Odds for Undiagnosed Prediabetes and Type 2 Diabetes in American Adults.

Authors:  Sean Mahoney; Adam Bradley; Logan Pitts; Stephanie Waletzko; Sheria G Robinson-Lane; Timothy Fairchild; Donna J Terbizan; Ryan McGrath
Journal:  Int J Environ Res Public Health       Date:  2020-06-30       Impact factor: 3.390

9.  Comparative predictive ability of visit-to-visit HbA1c variability measures for microvascular disease risk in type 2 diabetes.

Authors:  Chen-Yi Yang; Pei-Fang Su; Jo-Ying Hung; Huang-Tz Ou; Shihchen Kuo
Journal:  Cardiovasc Diabetol       Date:  2020-07-06       Impact factor: 9.951

10.  Association of Glycemic Control Trajectory with Short-Term Mortality in Diabetes Patients with High Cardiovascular Risk: a Joint Latent Class Modeling Study.

Authors:  Sridharan Raghavan; Wenhui G Liu; Seth A Berkowitz; Anna E Barón; Mary E Plomondon; Thomas M Maddox; Jane E B Reusch; P Michael Ho; Liron Caplan
Journal:  J Gen Intern Med       Date:  2020-04-24       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.